{"id":3545,"date":"2023-06-15T16:29:32","date_gmt":"2023-06-15T14:29:32","guid":{"rendered":"http:\/\/www.internalmed-journal.in.ua\/?p=3545"},"modified":"2023-08-11T13:40:04","modified_gmt":"2023-08-11T11:40:04","slug":"%d0%bc%d0%b5%d1%82%d0%b0%d0%b1%d0%be%d0%bb%d1%96%d1%87%d0%bd%d0%be-%d0%b0%d1%81%d0%be%d1%86%d1%96%d0%b9%d0%be%d0%b2%d0%b0%d0%bd%d0%b0-%d0%b6%d0%b8%d1%80%d0%be%d0%b2%d0%b0-%d1%85%d0%b2%d0%be%d1%80","status":"publish","type":"post","link":"http:\/\/www.internalmed-journal.in.ua\/en\/archives\/3545","title":{"rendered":"Metabolic-associated fatty liver disease and gut microbiota: pathogenetic relationships and therapeutic target"},"content":{"rendered":"

Prof. Zvyagintseva T.D., assoc. prof. Chernobay A.I. \u00a0<\/strong><\/p>\n

Kharkiv National Medical University <\/strong><\/p>\n

The article presents the characteristics of metabolically associated fatty liver disease (\u041c\u0410FLD) in combination with intestinal microbiota. The risk factors for the development of \u041c\u0410FLD, the importance of the \u00abmicrobiotaintestine-liver\u00bb axis in the progression of fatty liver disease and in the disruption of the intestinal microbiome with the development of intestinal dysbiosis, which leads to metabolic disorders in the body, are revealed. The use of the drug UDH\u0410 (Ursis) and coloprotector Zafacol 3D, which are means of pathogenetic therapy in patients with \u041c\u0410FLD and intestinal dysbiosis, is pathogenetically justified.<\/p>\n

Key words:<\/strong> metabolic-associated fatty liver disease (\u041cAFLD), gut microbiome, \u00abmicrobiota-gut-liver axis\u00bb, ursodeoxycholic acid, coloprotector.<\/p>\n

https:\/\/doi.org\/10.15407\/internalmed2023.02.004<\/strong><\/a><\/p>\n

Download.PDF (ukr)<\/strong><\/a><\/p>\n

Cite:<\/strong><\/p>\n

    \n
  1. \u0417\u0432\u044f\u0433\u0456\u043d\u0446\u0435\u0432\u0430, \u0422.\u0414. \u041c\u0435\u0442\u0430\u0431\u043e\u043b\u0456\u0447\u043d\u043e-\u0430\u0441\u043e\u0446\u0456\u0439\u043e\u0432\u0430\u043d\u0430 \u0436\u0438\u0440\u043e\u0432\u0430 \u0445\u0432\u043e\u0440\u043e\u0431\u0430 \u043f\u0435\u0447\u0456\u043d\u043a\u0438 \u0442\u0430 \u043c\u0456\u043a\u0440\u043e\u0431\u0456\u043e\u0442\u0430 \u043a\u0438\u0448\u0435\u0447\u043d\u0438\u043a\u0430: \u043f\u0430\u0442\u043e\u0433\u0435\u043d\u0435\u0442\u0438\u0447\u043d\u0456 \u0432\u0437\u0430\u0454\u043c\u043e\u0437\u0432\u2019\u044f\u0437\u043a\u0438 \u0442\u0430 \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u043d\u0456 \u043c\u0456\u0448\u0435\u043d\u0456 \/ \u0422.\u0414. \u0417\u0432\u044f\u0433\u0456\u043d\u0446\u0435\u0432\u0430, \u0410.\u0406. \u0427\u0435\u0440\u043d\u043e\u0431\u0430\u0439 \/\/ \u0421\u0445\u0456\u0434\u043d\u043e\u0454\u0432\u0440\u043e\u043f\u0435\u0439\u0441\u044c\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b \u0432\u043d\u0443\u0442\u0440\u0456\u0448\u043d\u044c\u043e\u0457 \u0442\u0430 \u0441\u0456\u043c\u0435\u0439\u043d\u043e\u0457 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0438. – 2023. – \u2116 2. – \u0421. 4-11. http:\/\/doi.org\/10.15407\/internalmed2023.02.004<\/li>\n
  2. Zviahintseva TD, Chernobai AI. [Metabolic-associated fatty liver disease and gut microbiota: pathogenetic relationships and therapeutic targets]. Shidnoevr. z. vnutr. simejnoi med. 2023;2:4-11. Ukrainian. http:\/\/doi.org\/10.15407\/internalmed2023.02.004<\/li>\n<\/ol>\n

    References:<\/strong><\/p>\n

      \n
    1. Vahrushev JaM, Lukashevich AP. Znachenie sindroma izbytochnogo bakterial’nogo rosta v narushenii metabolicheskih funkcij pecheni pri nealkogol’noj zhirovoj bolezni pecheni. Ter. arhiv. 2021;93(2):169\u2013173. Russian. DOI: 10.26442\/00403660.2021.02.200622.<\/li>\n
    2. Tarantino G, Balsano C, Santini S, Brienza G, Clemente I, Cosimini B, Sinatti G. It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?. International Journal of Molecular Sciences. 2021;22(24):13424. http:\/\/dx.doi.org\/10.3390\/ijms222413424<\/li>\n
    3. Dabravolski S, Bezsonov E, Baig M, Popkova T, Nedosugova L, Starodubova A, Orekhov A. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. International Journal of Molecular Sciences. 2021;22(9):4459. http:\/\/dx.doi.org\/10.3390\/ijms22094459<\/li>\n
    4. Yan T, Wang H, Cao L, Wang Q, Takahashi S, Yagai T, Li G, Krausz K, Wang G, Gonzalez F, Hao H. Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation. Drug Metabolism and Disposition. 2018;46(9):1310-1319. http:\/\/dx.doi.org\/10.1124\/dmd.118.082008<\/li>\n
    5. Sharpton S, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clinical Gastroenterology and Hepatology. 2019;17(2):296-306. http:\/\/dx.doi.org\/10.1016\/j.cgh.2018.08.065<\/li>\n
    6. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo\u2010Perez F, Guy C, Seed P, Rawls J, David L, Hunault G, Oberti F, Cal\u00e8s P, Diehl A. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-775. http:\/\/dx.doi.org\/10.1002\/hep.28356<\/li>\n
    7. Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Scientific Reports. 2016;6(1):. http:\/\/dx.doi.org\/10.1038\/srep32002<\/li>\n
    8. Zhang Y, Yan S, Sheng S, Qin Q, Chen J, Li W, Li T, Gao X, Wang L, Ang L, Ding S. Comparison of gut microbiota in male MAFLD patients with varying liver stiffness. Frontiers in Cellular and Infection Microbiology. 2022;12:. http:\/\/dx.doi.org\/10.3389\/fcimb.2022.873048<\/li>\n
    9. Shen F, Zheng R, Sun X, Ding W, Wang X, Fan J. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary & Pancreatic Diseases International. 2017;16(4):375-381. http:\/\/dx.doi.org\/10.1016\/s1499-3872(17)60019-5<\/li>\n
    10. Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019 Feb;11(2):e9302. doi: 10.15252\/emmm.201809302. PMID: 30591521; PMCID: PMC6365925.<\/li>\n
    11. Eslam M, Sanyal A, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, Kleiner D, Brunt E, Bugianesi E, Yki-J\u00e4rvinen H, Gr\u00f8nb\u00e6k H, Cortez-Pinto H, George J, Fan J, Valenti L, Abdelmalek M, Romero-Gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome P, Anstee Q, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin S, Harrison S, Kawaguchi T, Wong V, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. http:\/\/dx.doi.org\/10.1053\/j.gastro.2019.11.312<\/li>\n
    12. Zvyahinceva TD, Chernobaj A.I. Metabolichno asotsiiovana zhyrova khvoroba pechinky: fokus na metabolichni porushennia ta yikh korektsiiu. Medychna hazeta “Zdorovia Ukrainy”. Tematychnyi nomer \u00abHastroenterolohiia. Hepatolohiia. Koloproktolohiia\u00bb. 2021;4(62):15\u201316. Ukrainian<\/li>\n
    13. T.D. Zvyagintseva, A.I. Tchernobai The diverticular disease of colon and therapeutic possibilities of the colon protection. Su\u010dasna gastroenterolog\u00ec\u00e2<\/strong>. 2012;4 (66):67\u201375. Russian<\/li>\n
    14. T. D. Zvyagintseva, S. V. Gridneva. Colonprotection in gastroenterology. Su\u010dasna gastroenterolog\u00ec\u00e2<\/strong>. 2016;3 (89):47-56. Russian<\/li>\n
    15. Vallianou N, Liu J, Dalamaga M. What are the key points in the association between the gut microbiome and nonalcoholic fatty liver disease?. Metabolism Open. 2019;1:9-10. http:\/\/dx.doi.org\/10.1016\/j.metop.2019.02.003<\/li>\n
    16. Lau L, Wong S. Microbiota, Obesity and NAFLD. Advances in Experimental Medicine and Biology. 2018;:111-125. http:\/\/dx.doi.org\/10.1007\/978-981-10-8684-7_9<\/li>\n
    17. Schwenger K, Clermont-Dejean N, Allard J. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Reports. 2019;1(3):214-226. http:\/\/dx.doi.org\/10.1016\/j.jhepr.2019.04.004<\/li>\n
    18. Cavallari J, Pokrajac N, Zlitni S, Foley K, Henriksbo B, Schertzer J. NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice. American Journal of Physiology-Endocrinology and Metabolism. 2020;319(2):E305-E314. http:\/\/dx.doi.org\/10.1152\/ajpendo.00181.2020<\/li>\n
    19. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo\u2010Perez F, Guy C, Seed P, Rawls J, David L, Hunault G, Oberti F, Cal\u00e8s P, Diehl A. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-775. http:\/\/dx.doi.org\/10.1002\/hep.28356<\/li>\n
    20. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai P, Caussy C, Bettencourt R, Highlander S, Jones M, Sirlin C, Schnabl B, Brinkac L, Schork N, Chen C, Brenner D, Biggs W, Yooseph S, Venter J, Nelson K. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metabolism. 2017;25(5):1054-1062.e5. http:\/\/dx.doi.org\/10.1016\/j.cmet.2017.04.001<\/li>\n
    21. Lee G, You H, Bajaj J, Joo S, Yu J, Park S, Kang H, Park J, Kim J, Lee D, Lee S, Kim W, Ko G. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nature Communications. 2020;11(1):. http:\/\/dx.doi.org\/10.1038\/s41467-020-18754-5<\/li>\n
    22. Abenavoli L, Scarlata G, Scarpellini E, Boccuto L, Spagnuolo R, Tilocca B, Roncada P, Luzza F. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome. Medicina. 2023;59(3):594. http:\/\/dx.doi.org\/10.3390\/medicina59030594<\/li>\n
    23. Masarone M, Troisi J, Aglitti A, Torre P, Colucci A, Dallio M, Federico A, Balsano C, Persico M. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. Metabolomics. 2021;17(2):. http:\/\/dx.doi.org\/10.1007\/s11306-020-01756-1<\/li>\n
    24. Lanthier N, Delzenne N. Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?. Cells. 2022;11(17):2718. http:\/\/dx.doi.org\/10.3390\/cells11172718<\/li>\n
    25. Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom A, Verheij J, Nieuwdorp M, Cl\u00e9ment K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nature Reviews Gastroenterology &amp; Hepatology. 2020;17(5):279-297. http:\/\/dx.doi.org\/10.1038\/s41575-020-0269-9<\/li>\n
    26. Astbury S, Atallah E, Vijay A, Aithal G, Grove J, Valdes A. Lower gut microbiome diversity and higher abundance of proinflammatory genus <i>Collinsella<\/i> are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes. 2019;11(3):569-580. http:\/\/dx.doi.org\/10.1080\/19490976.2019.1681861<\/li>\n
    27. Bajaj J, Ng S, Schnabl B. Promises of microbiome-based therapies. Journal of Hepatology. 2022;76(6):1379-1391. http:\/\/dx.doi.org\/10.1016\/j.jhep.2021.12.003<\/li>\n
    28. Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, Zhang X, Wang Y, Kasper P, Bang C, Roderburg C, Tacke F, Steffen H, Goeser T, Kruglov A, Eckmann L, St\u00e4rkel P, Fouts D, Schnabl B. The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology. 2022;76(4):788-799. http:\/\/dx.doi.org\/10.1016\/j.jhep.2021.11.029<\/li>\n
    29. Shestakova EA, Pokrovskaja EV, Samsonova MD. Podhody k izucheniju vlijanija kishechnoj mikrobioty na razvitie metabolicheskih narushenij. Consilium Medicum. 2021;23(12):905\u2013909. DOI: 10.2644 2\/20751753.2021.12.201289. Russian<\/li>\n
    30. Dicheva DT, Andreev DN. Patogeneticheskoe i klinicheskoe znachenie osi \u00abmikrobiota \u2014 kishechnik \u2014 pechen’\u00bb. Medicinskij sovet. 2022;16(7):69\u201375. https:\/\/ doi.org\/10.21518\/2079-701X-2022-16-7-69-75. Russian<\/li>\n
    31. Shah A, Shanahan E, Macdonald G, Fletcher L, Ghasemi P, Morrison M, Jones M, Holtmann G. Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease. Seminars in Liver Disease. 2017;37(04):388-400. http:\/\/dx.doi.org\/10.1055\/s-0037-1608832<\/li>\n
    32. Wijarnpreecha K, Lou S, Watthanasuntorn K, Kroner P, Cheungpasitporn W, Lukens F, Pungpapong S, Keaveny A, Ungprasert P. Su1083 \u2013 Small Intestinal Bacterial Overgrowth and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2019;156(6):S-1271. http:\/\/dx.doi.org\/10.1016\/s0016-5085(19)40180-7<\/li>\n
    33. Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014Meta\u2010analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. http:\/\/dx.doi.org\/10.1002\/hep.28431<\/li>\n
    34. Xiang Z, Chen Y, Ma K, Ye Y, Zheng L, Yang Y, Li Y, Jin X. The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterology. 2013;13(1):. http:\/\/dx.doi.org\/10.1186\/1471-230x-13-140<\/li>\n
    35. S\u00e1nchez-Garc\u00eda A, Sahebkar A, Simental-Mend\u00eda M, Simental-Mend\u00eda L. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacological Research. 2018;135:144-149. http:\/\/dx.doi.org\/10.1016\/j.phrs.2018.08.008<\/li>\n
    36. Simental\u2010Mend\u00eda M, S\u00e1nchez\u2010Garc\u00eda A, Simental\u2010Mend\u00eda L. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta\u2010analysis of randomized placebo\u2010controlled clinical trials. British Journal of Clinical Pharmacology. 2020;86(8):1476-1488. http:\/\/dx.doi.org\/10.1111\/bcp.14311<\/li>\n
    37. Pearson T, Caporaso J, Yellowhair M, Bokulich N, Padi M, Roe D, Wertheim B, Linhart M, Martinez J, Bilagody C, Hornstra H, Alberts D, Lance P, Thompson P. Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development. Cancer Medicine. 2019;8(2):617-628. http:\/\/dx.doi.org\/10.1002\/cam4.1965<\/li>\n
    38. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard J, Rivi\u00e8re M, Sp\u00e9nard J. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. Journal of Hepatology. 2011;54(5):1011-1019. http:\/\/dx.doi.org\/10.1016\/j.jhep.2010.08.030<\/li>\n
    39. Tkach SM, Dorofeev AJe. The efficacy of Zafakol in the treatment of functional and inflammatory bowel diseases. Su\u010dasna gastroenterolog\u00ec\u00e2<\/strong>. 2017;2(94):111\u2013119. Russian<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Prof. Zvyagintseva T.D., assoc. prof. Chernobay A.I. \u00a0 Kharkiv National Medical University The article presents the characteristics of metabolically associated fatty liver disease (\u041c\u0410FLD) in combination with intestinal microbiota. The risk factors for the development of \u041c\u0410FLD, the importance of the \u00abmicrobiotaintestine-liver\u00bb axis in the progression of fatty liver disease and in the disruption of…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,67,108,109],"tags":[],"translation":{"provider":"WPGlobus","version":"2.12.2","language":"en","enabled_languages":["uk","en","ru"],"languages":{"uk":{"title":true,"content":true,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false}}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/3545"}],"collection":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/comments?post=3545"}],"version-history":[{"count":8,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/3545\/revisions"}],"predecessor-version":[{"id":3736,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/3545\/revisions\/3736"}],"wp:attachment":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/media?parent=3545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/categories?post=3545"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/tags?post=3545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}